Viewing Study NCT02207257

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:41 PM
Ignite Modification Date: 2026-02-25 @ 7:02 PM
Study NCT ID: NCT02207257
Status: COMPLETED
Last Update Posted: 2020-05-21
First Post: 2014-07-28
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban
Sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Anticoagulation Reversal View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PER977 View
None anticoagulation reversal View
None pharmacokinetics View
None edoxaban View
None whole blood clotting time View
None D-dimer View
None prothrombin fragments 1 and 2 View
None tissue factor pathway inhibitor View
None prothrombin time View